Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasisâ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Source
No articles found.
Synthorx is a biotechnology company focused on prolonging and improving the lives ...
Synthorx is a biotechnology company focused on ...
The Healthereum Patient Behavior Management platform is a full cycle communication...
The Healthereum Patient Behavior Management pla...
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...
Trillium Therapeutics Inc. is a clinical stage ...
La Jolla Pharmaceutical Company is a publicly traded biopharmaceutical company foc...
La Jolla Pharmaceutical Company is a publicly t...
Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâ...
Nemucore Medical Innovations is here to bring y...
GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and de...
GENFIT is a late-stage biopharmaceutical compan...
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the develop...
Aridis Pharmaceuticals, Inc. is a biopharmaceut...
Join the National Investor Network and get the latest information with your interests in mind.